Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Effects of PosBion® Supplementation on Intestinal Barrier Function in Adults With Irritable Bowel Syndrome

12 novembre 2026 mis à jour par: My Myracle Sdn.Bhd

Effects of PosBion® Supplementation on Barrier-Related Biomarkers in Adults With Irritable Bowel Syndrome

Postbiotic metabolites produced by beneficial bacteria may influence inflammatory responses, mucosal immunity, and host physiological signalling. PosBion® contains the proprietary cell-free metabolite preparations LPM5 and LPM11, derived from Lactiplantibacillus plantarum RS5 and RI11, respectively.

This study will evaluate changes in a panel of salivary biomarkers following 12 weeks of PosBion® supplementation in adults with irritable bowel syndrome (IBS). The biomarkers include myeloperoxidase (MPO), zonulin, lipopolysaccharide (LPS), LPS-binding protein (LBP), cortisol, serotonin, secretory immunoglobulin A (sIgA), lactoferrin, interleukin-8 (IL-8), immunoglobulin E (IgE), immunoglobulin M (IgM), and immunoglobulin G (IgG).

The study will primarily evaluate changes in inflammatory activity, while additional biomarkers will be used to explore mucosal immune, neuroendocrine, immunoglobulin, microbial exposure, and barrier-related responses following supplementation.

Aperçu de l'étude

Description détaillée

Irritable bowel syndrome is a disorder of gut-brain interaction associated with complex alterations in immune activity, gastrointestinal physiology, microbial-host interactions, and mucosal function. Microbial metabolites derived from beneficial bacteria have received increasing attention because of their potential immunomodulatory, anti-inflammatory, antioxidant, and mucosal effects.

PosBion® is a commercially available dietary supplement containing LPM5 and LPM11, proprietary cell-free metabolite preparations derived from Lactiplantibacillus plantarum RS5 and RI11, respectively. The finished preparations do not contain viable or inactivated bacterial cells.

Previous experimental investigations of RS5- and RI11-derived metabolites have demonstrated antimicrobial, antioxidant, immunomodulatory, and intestinal health-related activities. In particular, RI11-derived metabolites have been associated experimentally with modulation of inflammatory cytokines, antioxidant defence, and barrier-associated pathways.

The present study is designed as a prospective, single-arm, open-label interventional study to investigate longitudinal changes in salivary biomarkers following 12 weeks of PosBion® supplementation.

The principal biomarker of interest will be salivary IL-8 as a marker of inflammatory activity. Additional inflammatory markers will include MPO and lactoferrin. Mucosal and adaptive immune responses will be evaluated using sIgA, IgE, IgM, and IgG. Cortisol and serotonin will be investigated as neuroendocrine biomarkers.

Salivary zonulin, LPS, and LBP will also be assessed as exploratory biomarkers potentially related to microbial exposure and barrier-associated processes. Because these biomarkers are measured in saliva, they will not be interpreted as direct measurements of intestinal permeability.

Unstimulated saliva will be collected at baseline and after 4, 8, and 12 weeks of supplementation under standardized collection conditions. Biomarker concentrations will be quantified using commercially available validated assays according to the manufacturers' instructions.

The study is intended to provide mechanistic biomarker data on the biological responses associated with PosBion® supplementation rather than to evaluate changes in IBS symptom severity.

Type d'étude

Interventionnel

Inscription (Estimé)

55

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Adults aged 18 years or older
  • Experienced one or more symptoms suggestive of irritable bowel syndrome (IBS) prior to enrolment
  • Willing to comply with interventional plan
  • Willing to give consent

Exclusion Criteria:

  • History of chronic or serious medical conditions, including diabetes mellitus, cardiovascular disease, chronic kidney disease, cancer, or chronic respiratory disease
  • Current use of gastrointestinal health supplements
  • Current use of antibiotics or antiviral medications
  • Current use of probiotic, prebiotic, or postbiotic supplements
  • Major surgery within the previous 6 months.
  • Pregnant or lactating woman

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Soins de soutien
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: PosBion® Supplementation

Subjects will consume PosBion® for 12 consecutive weeks. Two sachets will be consumed daily, with one sachet taken after breakfast and one sachet after dinner. Saliva samples will be collected at baseline and Weeks 4, 8, and 12 for biomarker analysis.

PosBion® contains the proprietary cell-free metabolite preparations LPM5 and LPM11 derived from Lactiplantibacillus plantarum RS5 and RI11, respectively. Each sachet contains 2,500 mg LPM5 and 2,500 mg LPM11. Subjects will consume two sachets daily for 12 weeks, with one sachet taken after breakfast and one after dinner. The finished preparations do not contain viable or inactivated bacterial cells.

Autres noms:
  • PosBion®

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in Salivary Interleukin-8 (IL-8) Concentration
Délai: Baseline, Week 4, Week 8, and Week 12; primary comparison: baseline to Week 12

Salivary IL-8 concentration will be quantified using an enzyme-linked immunosorbent assay (ELISA). Changes over time will be evaluated, with the principal comparison between baseline and Week 12.

Baseline, Week 4, Week 8, and Week 12; primary comparison: baseline to Week 12
Change in Salivary Myeloperoxidase (MPO)
Délai: Baseline, Week 4, Week 8, and Week 12

Salivary MPO concentration will be quantified using ELISA as a marker associated with neutrophil and inflammatory activity.

Baseline, Week 4, Week 8, and Week 12
Change in Salivary Lactoferrin
Délai: Baseline, Week 4, Week 8, and Week 12

Salivary lactoferrin concentration will be quantified using ELISA as a marker associated with mucosal innate immune and inflammatory activity.

Baseline, Week 4, Week 8, and Week 12
Change in Salivary Secretory Immunoglobulin A (sIgA)
Délai: Baseline, Week 4, Week 8, and Week 12

Salivary sIgA concentration will be quantified as a marker of mucosal immune activity.

Baseline, Week 4, Week 8, and Week 12
Change in Salivary IgE
Délai: Baseline, Week 4, Week 8, and Week 12

Salivary IgE concentration will be quantified to evaluate changes in the immunoglobulin profile following supplementation.

Baseline, Week 4, Week 8, and Week 12
Change in Salivary IgM
Délai: Baseline, Week 4, Week 8, and Week 12

Salivary IgM concentration will be quantified to evaluate changes in the immunoglobulin profile following supplementation.

Baseline, Week 4, Week 8, and Week 12
Change in Salivary IgG
Délai: Baseline, Week 4, Week 8, and Week 12

Salivary IgG concentration will be quantified to evaluate changes in the immunoglobulin profile following supplementation.

Baseline, Week 4, Week 8, and Week 12

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Baseline, Week 4, Week 8, and Week 12
Délai: Baseline, Week 4, Week 8, and Week 12

Salivary cortisol concentration will be quantified as a neuroendocrine biomarker associated with physiological stress responses.

Baseline, Week 4, Week 8, and Week 12
Change in Salivary Serotonin
Délai: Baseline, Week 4, Week 8, and Week 12

Salivary serotonin concentration will be quantified as an exploratory neuroendocrine biomarker.

Baseline, Week 4, Week 8, and Week 12

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Change in Salivary Zonulin
Délai: Baseline, Week 4, Week 8, and Week 12

Salivary zonulin will be quantified as an exploratory biomarker potentially associated with barrier-related processes. The measurement will not be considered a direct assessment of intestinal permeability.

Baseline, Week 4, Week 8, and Week 12
Change in Salivary Lipopolysaccharide (LPS)
Délai: Baseline, Week 4, Week 8, and Week 12

Salivary LPS concentration will be evaluated as an exploratory marker of microbial exposure. Changes will not be interpreted as direct evidence of intestinal microbial translocation.

Baseline, Week 4, Week 8, and Week 12
Change in Salivary LPS-Binding Protein (LBP)
Délai: Baseline, Week 4, Week 8, and Week 12

Salivary LBP concentration will be evaluated as an exploratory biomarker related to host responses to microbial products.

Baseline, Week 4, Week 8, and Week 12

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Collaborateurs

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

15 novembre 2026

Achèvement primaire (Estimé)

15 février 2027

Achèvement de l'étude (Estimé)

15 mars 2027

Dates d'inscription aux études

Première soumission

12 novembre 2026

Première soumission répondant aux critères de contrôle qualité

12 novembre 2026

Première publication (Réel)

18 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

18 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

12 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

De-identified individual-level data underlying the reported study findings, together with relevant data dictionaries, may be made available to qualified researchers following publication.

Délai de partage IPD

Beginning approximately 6 months after publication of the primary study findings and available for up to 5 years.

Critères d'accès au partage IPD

Data may be provided to qualified researchers who submit a scientifically sound proposal. Requests will be reviewed by the principal investigator and/or study sponsor. Approved access may require a data-use agreement and secure transfer of de-identified data.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE
  • RSE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner